The majority of kidney cancer (around 80%) is characterised as clear-cell renal cell carcinoma (RCC), while the remaining 20% is non-clear cell RCC. Most of these are papillary RCC, but non-clear cell RCC also includes collecting duct, translocation, chromophobe and a variety of other rare tumour types. Because non-clear cell RCC is relatively rare, data […]
The National Institute of Health and Care Excellence (NICE) is planning to extend its use of real world data to help inform its independent committees who produce its guidance. NICE already makes use of a wide range of published scientific evidence for its guidance for the NHS on health technologies for a range of medical […]
Scientists at Yale University in America have discovered the molecular triggers for cancer cells to spread throughout the body (metastasise). They have also developed a tool which may detect the triggers in patients with certain cancers. The discovery could lead to new ways for treating cancer. The study was published this week in the journal […]
Telaglenastat is an oral glutaminase inhibitor and this is the first time it has been administered to humans. Glutaminase is a key enzyme that controls the glutamine pathway that is prominent in renal cell carcinoma (RCC) and important for the tumour to thrive in the body. In pre-clinical models, telaglenastat was found to synergise with […]
This discussion with Dr Paul Russo presents a case for cytoreductive nephrectomy, despite the results from the CARMENA trial, which did not show an overall survival advantage. The report concludes that careful selection of patients with intermediate-risk (not poor-risk) metastatic renal cell carcinoma (RCC) and cytoreductive nephrectomy performed by experienced surgeons, followed by treatment with […]
This review, published in HemOnc Today this week, discusses the various combination treatments available and in development for advanced/metastatic renal cell carcinoma (RCC) with world-leading experts in the management of kidney cancer. The review states that “Developing treatments that induce disease remission and eventually lead to cure is the highest priority for these patients.” Read […]
This review published in Clinical Genitourinary Cancer summarises the current treatments available for metastatic renal cell carcinoma (RCC), and the data from some of the most recent clinical trials, including CABOSUN, CheckMate 214, IMmotion151, and JAVELIN Renal 100. There is also a discussion about the use of biomarkers as predictors of outcomes for patients with […]
Around 12,500 new cases of renal cell carcinoma (RCC) are diagnosed annually in the UK, and about a third of these cases initially present with cancer that has spread to other parts of the body (non-localised or metastatic). Non-localised RCC has significantly worse 5-year survival outcomes compared with localised disease. The treatment options for patients […]
Elderly patients with metastatic renal cell carcinoma (RCC) are often underrepresented in clinical trials to treat the kidney cancer. However, according to a recent study published in JAMA Network Open Thirteen years of data were analysed from Medicare patients in the USA. Patients who received targeted therapies had more complex medical needs than those who […]
A recent study published in Journal of Clinical Medicine last month provides evidence for the expression of PD-1 and CTLA-4 receptors on white blood cells (tumour-infiltrating mononuclear cells) to be associated with a worse overall survival in patient with renal cell carcinoma (RCC). The combination of PD-1 and CTLA-4 expression in tumour-infiltrating mononuclear cells might […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
